KBI Biopharma announced that its subsidiary KBI Biopharma BVBA has begun operations at its newly completed laboratories in Leuven, Belgium.
The laboratories are co-located with JSR Life Sciences’ Amsphere A3 European manufacturing site and represent KBI’s first service offering based in Europe. KBI Biopharma BVBA initiated its first client-sponsored programs in May 2018.
KBI Biopharma BVBA has capabilities for GMP and non-GMP services including analytical development, formulation development, biopharmaceutical characterization and cGMP quality control testing for release and stability of drug substance and drug product.
To date, KBI has helped to advance more than 300 molecules in more than 70 unique health indications. By expanding its footprint into Europe, KBI will continue to accelerate an even broader range of drug development programs for its global client base.
KBI Biopharma is a biopharmaceutical Contract Development & Manufacturing Organization with extensive track record of successful programs. Its unique approach is applying the insight gained from our advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes.
KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapies for our clients. The company was founded in 1996 and is based in Durham, North Carolina (USA).